2-氯-3-硝基-6-三氟甲基吡啶 | 117519-08-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 2-氯-3-硝基-6-三氟甲基吡啶
• 中文别名: 2-氯-3-硝基-6-(三氟甲基)吡啶
• 英文名称: 2-chloro-3-nitro-6-(trifluoromethyl)pyridine
• 英文别名: 2-chloro-3-nitro-6-trifluoromethylpyridine
• CAS: 117519-08-1
• 化学式: C₆H₂ClF₃N₂O₂
• 分子量: 226.542
• InChiKey: RBLRRZSRLXGELK-UHFFFAOYSA-N

物化性质

• 沸点：
  242℃
• 密度：
  1.618
• 闪点：
  100℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-3-nitro-6-(trifluoromethyl)pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-3-nitro-6-(trifluoromethyl)pyridine
CAS number: 117519-08-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H2ClF3N2O2
Molecular weight: 226.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3-硝基-6-三氟甲基吡啶 在 铁粉 甲醇 、 potassium carbonate 、 氯化铵 、 三乙胺 、 乙酰氯 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 N-[2-(3-azetidinyloxy)-6-(trifluoromethyl)-3-pyridinyl]-2-chloro-4-pyridinecarboxamide
  参考文献：
  名称：

  [EN] PESTICIDAL 3-(ARYLOXY)AZACYCLOALKANES
  [FR] 3-(ARYLOXY)AZACYCLOALCANES PESTICIDES

  摘要：

  本文揭示了Formula 1的化合物，包括所有立体异构体、N-氧化物和盐，其中A1为N或CR7；A2为N或CR8；A3为N或CR9；A4为N或CR10；前提是A1、A2、A3和A4中不超过两个是N；T为O、S(O)k或NR36；L为-C(R11)=C(R12)-，其中与R11结合的碳原子同时也与CR4R5结合，与R12结合的碳原子同时也与R6结合；或者1,4-二苯基烯，可选地取代多达4个由R13独立选择的取代基；或者C(R34)(R35)-Z-，其中与R34和R35结合的碳原子同时也与CR4R5结合，Z与R6结合；Z为O、S(O)m、NR37或CR38R39；R1为苯基或5-或6-成员的杂环芳香环，可选地取代多达5个由R14独立选择的取代基；R6为苯基或5-或6-成员的杂环芳香环，可选地取代多达5个由R22独立选择的取代基；s为1、2或3；t为1或2；前提是s和t的总和为2、3或4；R2、R3、R4、R5、R7、R8、R9、R10、R11、R12、R13、R14、R22、R34、R35、R36、R37、R38、R39、W、k、m和n的定义如披露中所述。还披露了含有Formula 1化合物的组合物以及用于控制无脊椎动物害虫的方法，包括将无脊椎动物害虫或其环境与本发明的化合物或组合物的生物有效量接触。

  公开号：

  WO2012012366A1
• 作为产物：
  描述：

  3-氨基-2-氯-6-三氟甲基吡啶 在 硫酸 、 双氧水 作用下， 反应 20.0h， 生成 2-氯-3-硝基-6-三氟甲基吡啶
  参考文献：
  名称：

  [EN] PESTICIDAL 3-(ARYLOXY)AZACYCLOALKANES
  [FR] 3-(ARYLOXY)AZACYCLOALCANES PESTICIDES

  摘要：

  本文揭示了Formula 1的化合物，包括所有立体异构体、N-氧化物和盐，其中A1为N或CR7；A2为N或CR8；A3为N或CR9；A4为N或CR10；前提是A1、A2、A3和A4中不超过两个是N；T为O、S(O)k或NR36；L为-C(R11)=C(R12)-，其中与R11结合的碳原子同时也与CR4R5结合，与R12结合的碳原子同时也与R6结合；或者1,4-二苯基烯，可选地取代多达4个由R13独立选择的取代基；或者C(R34)(R35)-Z-，其中与R34和R35结合的碳原子同时也与CR4R5结合，Z与R6结合；Z为O、S(O)m、NR37或CR38R39；R1为苯基或5-或6-成员的杂环芳香环，可选地取代多达5个由R14独立选择的取代基；R6为苯基或5-或6-成员的杂环芳香环，可选地取代多达5个由R22独立选择的取代基；s为1、2或3；t为1或2；前提是s和t的总和为2、3或4；R2、R3、R4、R5、R7、R8、R9、R10、R11、R12、R13、R14、R22、R34、R35、R36、R37、R38、R39、W、k、m和n的定义如披露中所述。还披露了含有Formula 1化合物的组合物以及用于控制无脊椎动物害虫的方法，包括将无脊椎动物害虫或其环境与本发明的化合物或组合物的生物有效量接触。

  公开号：

  WO2012012366A1

文献信息

• [EN] HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS<br/>[FR] DÉRIVÉS AROMATIQUES HÉTÉROBICYCLIQUES ET HÉTÉROAROMATIQUES POUR LE TRAITEMENT DE TROUBLES LIÉS À LA FERROPTOSE
  申请人：COLLABORATIVE MEDICINAL DEV LLC

  公开号：WO2020185738A1

  公开（公告）日：2020-09-17

  The present application discloses heteroaromatic and heterobicyclic aromatic derivative compounds and compositions, and methods for treating ferroptosis-related disorders and diseases in patients using the compounds and compositions as disclosed herein.

  本申请公开了杂芳和杂双环芳香衍生物化合物和组合物，以及利用所公开的化合物和组合物治疗患者的铁死亡相关疾病和疾病的方法。
• [EN] AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS<br/>[FR] AZABENZIMIDAZOLES ET LEUR UTILISATION EN TANT QUE MODULATEURS DES RÉCEPTEURS AMPA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016176460A1

  公开（公告）日：2016-11-03

  Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [formula (I) should be inserted here]. Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

  本文件提供了公式(I)的化合物，以及药学上可接受的盐、N-氧化物或溶剂化物[此处应插入公式(I)]。此外，还提供了包含公式(I)化合物的药物组合物以及使用公式(I)化合物的方法。
• [EN] NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE À SUBSTITUTION HÉTÉROAROMATIQUE À 6 CHAÎNONS UTILISÉS COMME INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017125534A1

  公开（公告）日：2017-07-27

  The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及公式（I）的药物制剂，用于治疗和/或预防哺乳动物，特别是用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病的NF-KB诱导激酶（NIK - 也称为MAP3K14）抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病以及自身免疫性疾病的用途。
• [EN] N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-ARYLE MONOCYCLIQUES, N'-PYRAZOLYL-URÉE, THIOURÉE, GUANIDINE ET CYANOGUANIDINE UTILES COMME INHIBITEURS DE TRKA KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078325A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  化合物的公式(I)或其立体异构体、互变异构体、或其药学上可接受的盐、溶剂合物或前药，其中环A、环C和X如本文所定义，是TrkA激酶的抑制剂，并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
• Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity
  作者：Brodie L. Bailey、William Nguyen、Anna Ngo、Christopher D. Goodman、Maria R. Gancheva、Paola Favuzza、Laura M. Sanz、Francisco-Javier Gamo、Kym N. Lowes、Geoffrey I. McFadden、Danny W. Wilson、Benoît Laleu、Stephen Brand、Paul F. Jackson、Alan F. Cowman、Brad E. Sleebs

  DOI：10.1016/j.bioorg.2021.105244

  日期：2021.10

  the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant

  疟疾是由从该属的寄生虫毁灭性的寄生虫病疟原虫。据报道，所有临床上可用的抗疟药都存在治疗耐药性，威胁到我们控制疾病的能力，因此持续需要开发新型抗疟药。为了实现这一目标，我们从 Janssen Jumpstarter 库的高通量筛选中针对恶性疟原虫的无性阶段鉴定了 2-（N-苯基甲酰胺）三唑并嘧啶类寄生虫。在这里，我们描述了已识别类别的结构活性关系和无性阶段活性的优化，同时保持对人 HepG2 细胞系的选择性。本研究中最有效的类似物显示出对恶性疟原虫多药耐药菌株和诺氏疟原虫无性寄生虫的等效活性。无性阶段表型研究确定三唑并嘧啶类在滋养体阶段捕获寄生虫，但这些寄生虫很可能在第二个无性周期之前仍然具有代谢活性，因此具有中度至缓慢的作用开始。在体外观察到中心羧酰胺的非 NADPH 依赖性降解和低水溶性ADME 分析。一个重大挑战仍然是纠正这些缺陷，以进一步推进 2-( N-苯基甲酰胺) 三唑并嘧啶支架